Geron Corporation Reports Fourth Quarter and Full Year 2019 Financial Results and 2020 Milestones

Go back to Geron Corporation Reports Fourth Quarter and Full Year 2019 Financial Results and 2020 Milestones

Geron Corp (GERN) Tops Q4 EPS by 5c

March 12, 2020 4:45 PM EDT

Geron Corp (NASDAQ: GERN) reported Q4 EPS of ($0.15), $0.05 better than the analyst estimate of ($0.20).

2019 was a pivotal year for Geron as we completed the imetelstat program transition, assembled an impressive in-house team with a proven track record in drug development, and advanced imetelstat... More